89bio to net $275M from stock of­fer­ing; As­sem­bly Bio to pause work on one HBV in­hibitor pro­gram

San Fran­cis­co-based biotech 89bio an­nounced on Fri­day that it ex­pects to rake in $275 mil­lion on a stock of­fer­ing. The raise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.